Tuberculosis
We are entering an exciting period of detection of disease.
Blookmington, MN (PRWEB) February 20, 2015
Medical device company Ancon Medical Inc. has confirmed today that it has detected Tuberclosis biomarkers using its revolutionary new breath screening technology NBT-GC that makes it possible to easily find the indicators for deadly and dangerous diseases such as TB at their earliest stages. The potential benefits of the Nanoparticle Biomarker Tagging (NBT) technology are far ranging, from conducting mass screenings for contagious diseases, to identifying Lung Cancer and Tuberculosis.
The tests were carried out in a clean laboratory environment and Ancon Medical will soon undergo further tests in what is referred to as a dirty environment where they are confident this will be a success and take breath detection of Tuberclosis to the next level. With its NBT technology, Ancon Medical can give healthcare providers a versatile disease screening device that delivers a wide range of features, including unmatched sensitivity, portability, and ease of use and fast results. Most importantly, because NBT works by scanning breath, this simple, non-invasive procedure makes the technology accessible to much wider range of the population.
NBT works by detecting biomarkers in exhaled breath, and it’s able to find these DNA-protein controlled volatile organic compounds (VOCs) in lower concentrations than any similar breath screening technology. The NBT technology can measure down to one ion in 10,000 cubic centimeters, giving it the unprecedented sensitivity to find a single biomarker molecule and is the leading technology in this field.
“We are entering an exciting period of detection of disease. No matter what the disease, an early diagnosis will always give medical professionals the advantage of a head start in treatment, isolation and prevention. The difference can be measured in better treatment, delivered faster, that saves lives,” said Wesley Baker, Ancon Medical president.
TB is one of the world’s leading causes of death, primarily because diagnosis generally requires a blood test and chest x-rays, making it often go undetected until too late. “Ancon Medical’s NBT device can change the story on Tuberclosis, and a host of diseases that unnecessarily inflict misery on the world we live in,” Baker said. “With funding, research, and commercialization we can give healthcare workers the tools to fight these terrible diseases.”
NBT has potential to be a powerful screening tool for other diseases, especially infectious diseases that can rapidly spread through underdeveloped countries. For Ebola, NBT is sensitive enough to detect the virus within an individual’s breath within 24 to 72 hours of exposure.
